中 | EN
Home
About
Products
R&D
Manufacturing
Partnering
News
IR
Sustainability
Join Us

News

Academic Meeting of Domestic and Overseas Experts — SANBEXIN® Opens the Door to Brain Cell Protection

In terms of treatments for stroke, "reperfusion therapy" has become the mainstream. What are the effective ways to improve the prognosis o...

2023-03-29
XIANNUOXIN®: The Key to Pandemic Prevention and Control for Vulnerable Populations

On the morning of Feb. 26, 2023, the release conference of XIANNUOXIN®, the first domestic 3CL anti-COVID-19 innovative drug, was held in Haik...

2023-03-29
NMPA Commissioner Jiao Hong Investigated the Quality Assurance and Supply Guarantee of the Anti-COVID-19 Innovative Drug XIANNUOXIN®

On the morning of Feb. 17, 2023, National Medical Products Administration (NMPA) Commissioner Jiao Hong and her delegation visited Hainan Simcere Phar...

2023-03-29
COSELA®, the first and only proactive multilineage myeloprotection therapy for chemotherapy-induced myelosuppression, was launched in China, greatly improving the accessibility of imported drugs urgently needed in clinical practice

On Feb. 12, 2023, Simcere Zaiming, a company that focuses on the development and commercialization of innovative oncology drugs, held a well-attende...

2023-03-23
read more

6,500+

Staff

40+

Current Brands of Products

50+

Innovative Product Candidates

1,900+

Covering Class III Hospitals

17,000+

Covering Other Hospitals & Medical Institutions

Partnering

Therapeutic Areas

Telephone: 025-85566666 Fax：025-85262330

Address: 699-18 Xuanwu Avenue Nanjing China

Zipcode：210042

Fax：025-85471729

Su ICP Bei No. 10205883 Su Gong Wang An Bei No. 32010202010345
Su ICP Bei No. 08104641-3 | (Su)–Non-business–2018-0092 (Internet Drug Information Service Qualification Certificate)
© Copyright 2016 Jiangsu Simcere Pharmaceutical Co., Ltd. 版权所有 All Rights Reserved.